We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03720626
Expanded Access Status : Available
First Posted : October 25, 2018
Last Update Posted : December 23, 2022
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this Cohort Treatment Plan is to allow access to crizanlizumab (SEG101) for eligible patients diagnosed with sickle cell disease (SCD) to prevent or reduce the frequency of vaso-occlusive crises (VOC). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Condition or disease Intervention/treatment
Sickle Cell Disease Drug: crizanlizumab

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Managed Access Program (MAP) Cohort Treatment Plan CSEG101A2001M to Provide Access to Crizanlizumab for Sickle Cell Disease Patients With History of Vaso-occlusive Crisis

Intervention Details:
  • Drug: crizanlizumab
    IV formulation with 30 min infusion, 5mg/kg dosage
    Other Name: SEG101

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

Written patient informed consent must be obtained prior to start of treatment, including all necessary consents (or their legal representatives, where applicable).

  1. 1. Male or female, 12 years of age (inclusive) or older on the day of informed consent signature.
  2. Confirmed diagnosis of sickle cell disease by hemoglobin electrophoresis or high performance liquid chromatography (HPLC) [performed locally]. All sickle cell disease genotypes are eligible (HbSS, HbSβ0, HbSC, HbSβ+, and others).
  3. History of recurrent VOC as assessed by the Treating Physician.
  4. Patients receiving HU/HC, L-glutamine (Endari), or other therapies as prevention therapy and continue to experience VOC while on any of these treatments.

    • Patients can continue taking the preventive therapy.

  5. Patient is not a candidate to be treated with alternative treatment options or has discontinued alternative treatments due to unacceptable benefit risk as documented by the Treating Physician.
  6. Patient must meet the following laboratory values prior to treatment:

    • Absolute Neutrophil Count ≥1.0 x 10^9/L
    • Platelets ≥ 75 x 10^9/L
    • Hemoglobin (Hgb) ≥ 4.0 g/dL
    • Estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2 using CKD-EPI formula
    • Direct (conjugated) bilirubin ≤ 2.0 x ULN
    • Alanine transaminase (ALT) ≤ 3.0 x ULN
  7. Received standard age-appropriate care for SCD, including an up-to-date record of immunizations, as per local requirements
  8. Patients who are clinically stable and are in a non-crisis state at the time of treatment start

Exclusion criteria

Patients eligible for this Treatment Plan must not meet any of the following criteria:

  1. Contraindication or hypersensitivity to any drug or metabolites from similar class as crizanlizumab drug or to any excipients of the drug formulation.
  2. History of severe hypersensitivity reaction to other monoclonal antibodies, which in the opinion of the Treating Physician may pose an increased risk of serious infusion reaction.
  3. Has documented immunogenicity to a prior biologic.
  4. Pregnant or nursing women
  5. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 15 weeks after stopping treatment. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking crizanlizumab. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to treatment). The vasectomized male partner should be the sole partner for that patient
    • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
    • In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before starting treatment.
    • Women of child bearing potential must be informed that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the MAP they must adhere to the contraception requirement for the duration of treatment.
  6. Patients with bleeding disorders
  7. Known history of testing positive for Human Immunodeficiency Virus (HIV) infection
  8. Patients with active Hepatitis B infections (HBsAg positive)

    - Note: Patients with antecedent but no active Hepatitis B (i.e. anti-HBc positive, HBsAg and HBV-DNA negative) are eligible

  9. Patients with positive test for hepatitis C ribonucleic acid (HCV RNA)

    - Note: Patients in whom HCV infection resolved spontaneously (positive HCV antibodies without detectable HCV-RNA) or those that achieved a sustained virological response after antiviral treatment and show absence of detectable HCV RNA ≥ 6 months (with the use of IFN-free regimes) or ≥ 12 months (with the use of IFN-based regimes) after cessation of antiviral treatment are eligible

  10. Significant active infection or immune deficiency (including chronic use of immunosuppressive drugs)
  11. Malignant disease. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to treatment; completely resected basal cell and squamous cell skin cancers and any completely resected carcinoma in situ
  12. Has a serious mental or physical illness, which, in the opinion of the Treating Physician would compromise compliance to treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03720626

Layout table for location contacts
Contact: Novartis Pharmaceuticals +41613241111 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals

Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03720626    
Other Study ID Numbers: CSEG101A2001M
First Posted: October 25, 2018    Key Record Dates
Last Update Posted: December 23, 2022
Last Verified: December 2022
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Sickle cell disease
sickle cell anemia
vaso-occlusive crisis
monoclonal antibody
Anemia, Sickle Cell
HbS Disease
Hemoglobin SC Disease
Sickle Cell Disorders
Sickling Disorder Due to Hemoglobin S
Hb Sβ+-thalassemia
Hb Sβ0-thalassemia
Expanded Access Use
Pain Crisis
Compassionate Use
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn